In light of COVID-19 precaution measures, we remind that all ImmuniWeb products can be easily configured and safely paid online without any human contact or paperwork.

Total Tests:
Stay in Touch

Weekly newsletter on AI, Application Security & Cybercrime

Your data will stay confidential Private and Confidential

ImmuniWeb® hybrid on-demand web application security assessment is now in open Beta

March 12, 2014

ImmuniWeb®, our innovative web application security assessment that combines manual penetration testing with cutting-edge vulnerability scanning into a single, comprehensive and highly-efficient SaaS solution, is now available in open Beta!

ImmuniWeb®, a hybrid web application security assessment SaaS developed by High-Tech Bridge, is now in open Beta! The hybrid approach to web application security testing, on which ImmuniWeb is based, combines manual penetration testing with cutting-edge vulnerability scanning into a single, comprehensive and highly-efficient solution.

ImmuniWeb provides SMEs and large corporations with the ability to test their website security by professional penetration testers for a price of an automated vulnerability assessment.

Introduced by High-Tech Bridge to the market in 2013 the hybrid approach to testing web application security benefits from the ease-of-use, unbeatable quality and competitive pricing combined with the on-demand SaaS delivery model. ImmuniWeb SaaS was successfully passed as CWE and CVE compatibility certification by MITRE in summer 2013.

ImmuniWeb assessment technical details and specifications are available here.

Compare Web Application Security Assessments with ImmuniWeb®

ImmuniWeb SaaS was launched in closed Beta in May 2013 to a limited audience. Since then ImmuniWeb has been tested and positively rated by many journalists from well-known publications including the Financial Times and PC Mag. Leading security writers and analysts such as Graham Cluley also reviewed ImmuniWeb – Cluley used it to assess security of his own website. In November 2013 The International Telecommunication Union (ITU) announced the use of ImmuniWeb as part of the toolset for ensuring that the governmental websites of ITU’s Member States are secure.

According to Alexander Michael, Director of ICT Consulting at Frost & Sullivan "It certainly appears that the hybrid approach [of web application security testing], introduced to the global market by ImmuniWeb, represents a highly efficient, new generation solution for SMBs, offering speed, simplicity, cost-effectiveness and additional quality, afforded by the parallel manual penetration testing."

From Monday, 10th of March 2014, anyone can register for free on the ImmuniWeb Portal and, following manual account verification, make full use of the security assessment service.

Mr. Ilia Kolochenko, CEO of High-Tech Bridge, says "After four years of development we are almost ready to launch ImmuniWeb in fully operational mode. Open Beta is the last step before the service will become fully public. We just want to get as many opinions and requests for additional features as possible to make sure that every customer will be totally satisfied with the service."

About High-Tech Bridge
High-Tech Bridge SA is a leading provider of information security services, such as penetration testing, network security auditing, consulting and computer crime forensics. In 2012 Frost & Sullivan has recognized High-Tech Bridge as one of the market leaders and best service providers in the ethical hacking industry. High-Tech Bridge Security Research Lab helped various software vendors improving security of their products, including such vendors as Microsoft, IBM, Novell, McAfee, Sony, HP, Samsung, OpenOffice, Corel, OpenX, Joomla, WordPress, UMI.CMS, and hundreds of others.

About ImmuniWeb®
ImmuniWeb® is a next-generation on-demand web application security assessment solution with online Software-as-a-Service delivery model. It is a unique hybrid of cutting-edge web security scanner and accurate manual web application penetration test. Any additional information about ImmuniWeb can be found at

User Comments
Add Comment

Ask a Question